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Randomised trial of candesartan and enalapril (RACE) in the treatment of
hypertension – final results
BMY Cheung, CY Law, PCW Fung, KWT Tsang, KCB Tan, CR Kumana, CP Lau. University Department of Medicine,
Queen Mary Hospital, Hong Kong.
Introduction: The renin-angiotensin system plays an important part in the pathophysiology of hypertension. We compared two ways of
blocking the system, using an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker.
Method: 22 hypertensive patients (16 men, 6 women; age 47±10 yrs) were randomised to either candesartan 8 mg or enalapril 10 mg
daily for 3 months. The dose could be doubled after 6 weeks for blood pressure control. Ambulatory blood pressure monitoring was
performed before randomisation and before the final visit. Echocardiography was performed at randomization, 2 and 12 weeks. Flow-
mediated dilatation was measured at the brachial artery to assess endothelial function. Exhaled nitric oxide was measured using an
integrated chemiluminescent system. The coefficient of variation of left ventricular mass index (LVMI), flow-mediated dilatation (FMD) and
nitric oxide measurement were 7%, 5% and 3% respectively.
Results: Candesartan and enalapril both significantly lowered systolic and diastolic blood pressure. This was confirmed by ambulatory
blood pressure monitoring.
There were no significant differences between the treatments in their effect on LVMI and exhaled nitric oxide. Changes in LVMI corre-
lated strongly with changes in the ambulatory systolic blood pressure (r=0.62, p=0.02) and diastolic blood pressure (r=0.61, p=0.02).
FMD increased with enalapril but not candesartan treatment (p=0.04). Neither treatment significantly altered plasma potassium, creatinine,
renin and aldosterone. Fasting blood glucose decreased significantly from 5.6±0.4 to 5.1±0.3 mmol/L in the enalapril group (p=0.01)
only.
Conclusions: Both drugs are efficacious in lowering blood pressure. Candesartan tended to lower blood pressure more than enalapril,
which might be the result of the dosages used. Enalapril appears to have a favourable effect on blood glucose and endothelial function. We
conclude that candesartan may be used as an alternative to enalapril in the treatment of hypertension, particularly in those who are
intolerant of the latter.
Baseline SBP Final SBP Baseline DBP Final DBP Baseline LVMI Final LVMI
candesartan 158.2±5.7 134.5±4.3* 100.3±3.9 85.3±3.2* 139.8±12.5 134.9±11.1
enalapril 159.8±4.0 145.3±6.1**  97.4±3.0 87.0±3.4* 127.3±6.4 134.5±8.0
*p<0.05 vs. baseline; ** p<0.05 vs. baseline and p=0.05 vs. candesartan
Urotensin II in hypertension
BMY Cheung, R Leung, LYF Wong, YB Man, CP Lau, CR Kumana. University Department of Medicine, Queen Mary
Hospital, Hong Kong
Introduction: Urotensin II (UII) is an 11 amino acid cyclic peptide and is the most potent vasoconstrictor known.
UII receptors are found in the heart and arterial vessels, including atherosclerotic plaques, suggesting that urotensin
II has a role in cardiovascular diseases. UII circulates in human plasma and its plasma concentration is raised in
cardiac and renal failure. The role of UII in hypertension has not been investigated.
Method: We studied the plasma level of UII levels in 22 hypertensive subjects (68% male, age 51±10 yrs) and 37
normal controls (49% male, age 51±12 yrs ) with consent from the subjects and approval from the Ethics Committee.
Plasma UII was measured using a radioimmunoassay.
Results: Plasma UII was 10.6±1.4 pg/ml in normotensive controls and 21.0±3.6 pg/ml in hypertensive subjects
(p=0.003). UII in men and women were not significantly different. UII did not vary significantly with age in normal
healthy subjects (r=0.09, NS) but was inversely related to age in hypertensive subjects (r=-0.35, p=0.025). In hyper-
tensive subjects but not in control subjects, UII was related to diastolic blood pressure (r=0.31, p<0.05). UII is not
related to plasma creatinine or creatinine clearance (p>0.05).
Conclusions: Our results raise the possibility that this novel and potent vasoconstrictor may have an aetiological
role in hypertension or may be involved in the complications of hypertension. Antagonists to urotensin II might be
antihypertensive agents with a novel mechanism of action.
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The Heart Protection Study findings with simvastatin reanalysed by number
needed to treat
CR Kumana, BMY Cheung & IJ Lauder.† Departments of Medicine and Statistics & Actuarial Science,† The University of
Hong Kong, Queen Mary Hospital, Hong Kong
Introduction: Number Needed toTreat (NNT) is superior to Relative Risk Reduction (RRR) as a means of assessing clinical trial results. We therefore opted to
compare relevant RRRs and NNTs in the MRC/BHF Heart Protection Study(HPS) with Simvastatin the largest randomized trial of coronary heart disease (CHD)
prevention to date, which recruited patients with prior CHD, diabetes or hypertension [HPS Collaborative Group 2002 Lancet 360:7-22].
Methods: Using an Excel spreadsheet to enter event rates, NNTs and respective 95% CIs were calculated and compared with corresponding published (or derived)
RRRs.
Results: Respective event rates, 5 year NNTs & CIs are shown in the table.
Conclusions: NNTs are more discriminating than RRRs. They confirm that the benefits of statins: are clinically significant in terms of all-cause mortality and stroke,
and that for major vascular events they are similar in persons with CHD only or diabetes only and in all cholesterol level and age categories.
Outcome of Interest Event Rate (%) %RRR NNT
Simvastatin Placebo (95% CIs) (95% CIs)
All Cause Mortality 12.9 14.7 12 (5 to 18.) 57 (37 to 128)
Vascular Mortality 7.6 9.1 17 (8 to 24) 66 (44 to 134)
Non-vascular Mortality 5.3 5.6 4 (* to 15) 444 (* to 117)
1st Major CHD Event 8.7 11.8 26 (19 to 32) 32.7 (26 to 45)
1st Stroke 4.3 5.7 24 (14 to 33) 73 (50 to 131)
Revascularisaton 9.1 11.7 22 (15 to 29) 39 (29 to 58)
1st Major Vascular Event
<5.0 17.7 23.1 23 (12 to 33) 19 (13 to 35)
Total Cholesterol (mmol/L) ≥5.0 <6.0 16.9 24.5 23 (15 to 30) 18 (13 to 27)
≥6.0 21.6 26.8 19 (12 to 26) 19 (14 to 30)
<65 16.9 22.1 23 (16 to 30) 19 (15 to 28)
Age   (years) ≥65 <70 20.9 27.2 23 (14 to 32) 16 (11 to 26)
≥70 23.6 28.7 18 (9 to 26) 20 (14 to 36)
Prior CHD only 16.8 22.5 25 (17 to 33) 18 (13 to 26)
Prior Diabetes only 13.8 18.6 26 (13 to 37) 21 (14 to 40)
Prior CHD + Diabetes 33.4 37.8 11 (* to 24) 23 (12 to *)
* Denotes a negative value indicating an increased event rate in the treated group, renderng further analysis inappropriate; 1st major coronary event = non-fatal MI
or CHD death; Revascularisation = coronary and non-coronary bypass and angioplasty; 1st major vascular event = 1st major coronary event, stroke or revascularisation
CVS-23
CVS-24 Endotoxin increases adrenomedullin expression in heart, lung and mesenteric
artery
YY Li, F Tang1 and BMY Cheung2
Department of Physiology1 and Department of Medicine,2 The University of Hong Kong
Introduction: Previous studies have shown that the circulating levels of adrenomedullin (AM) are elevated during
inflammation. The levels of AM and its messenger RNA (mRNA) in various tissues during the time course of
inflammation remain to be determined.
Method: Inflammation was induced in rats by intraperitoneal injection of lipopolysaccharide (LPS, 10mg/kg). The
tissues were harvested at 0, 1, 3 and 6 hours after LPS administration. Tissue levels of AM were determined
by radioimmunoassay. The gene expression levels of AM were determined by solution hybridization-RNase
protection assay of preproAM mRNA levels.
Results: PreproAM mRNA levels were increased in mesenteric artery and right atrium at 1 hour, in the left
ventricle and the lung at 3 and 6 hours and in the right ventricle at 6 hours, after LPS injection. AM levels in the
mesenteric artery were increased at 1, 3 and 6 hours and at 3 and 6 hours in the lung after LPS injection.
Conclusions: There is an increase in AM release in the lung, so it may be an important organ for AM secretion in
the septic state. However, the response of the lung and the mesenteric artery to LPS in terms of AM secretion
appears to be different.
